# Biotechnology sector quarterly earnings

> Developing situation record from CLSTR: https://clstr.news/situations/biotechnology-sector-quarterly-earnings
> Updated: 2026-10-31T17:08:01.000Z. Sources: 7. Developments: 2.

The biotechnology sector reported varied quarterly financial results. Regeneron announced a 36% year-over-year revenue increase to $5.1 billion, driven by sales of Dupixent and EYLEA HD, alongside positive early clinical trial data for a gene-silencing therapy. 

Amgen reported a 10% year-over-year revenue increase to $10.1 billion for its second quarter. The company is transitioning toward newer therapies like Tezspire and Imdelltra to offset upcoming patent expirations and declining sales in older immunology medicines.

## Timeline

### 2026-10-31: Amgen reports 10% revenue growth in second quarter

Amgen reported a 10% increase in second-quarter revenue to $10.1 billion, driven by a diversified portfolio of high-growth biotech products.

2 sources. https://clstr.news/cluster/amgen-reports-10-revenue-growth-in-second-quarter

### 2026-10-30: Regeneron reports 36% revenue growth in third quarter

Regeneron reported $5.1 billion in Q3 2026 revenue, a 36% year-over-year increase driven by Dupixent and EYLEA HD sales.

6 sources. https://clstr.news/cluster/regeneron-reports-strong-q3-growth-driven-by-drug-demand

---
Cite as: Biotechnology sector quarterly earnings. CLSTR, https://clstr.news/situations/biotechnology-sector-quarterly-earnings